England H3N2 Has Abolished HA Glycosylation Site



	Home	Founder	What's New	In The News	Consulting



H1N1 Consulting Paradigm Shift Viral Evolution Intervention Monitoring Vaccine Screening Vaccine Development Expression Profiling Drug Discovery Custom Therapies Patents	Audio:Oct18 Nov15 Nov30 Dec20 twitter Commentary England H3N2 Has Abolished HA Glycosylation Site Recombinomics Commentary 23:55 January 3, 2013 The Health Protection Agency (HPA) has released recent H3N2 sequences from Newcastle (A/ENG/574/2012, collected October 22 and A/ENG/570/2012, collected October 23). The HA sequences from both isolates are identical and closely related to A/Iowa/14/2012, which the CDC has designated as a low reactor. Like the Iowa isolate, the HPA sequences have T128A, which abolishes the glycosylation site at position 126, which was also present in the Fujian-like H3N2 target, A/Wyoming/3/2003 used in the 2004/2005 season, (A/reassortant/NYMC X-147). This change, as well as the associated changes in the Iowa isolate, is widespread in the United States, signaling serious vaccine failures, CDC FluView claims of matches in 99.3% of H3N2 sequences not withstanding. H3N2 is rapidly spreading in the United States, leading to physician claims of vaccine failures. In addition to the presence of these changes in 2 of 2 recent sequences from England, these changes are also common in Japan and Taiwan raising additional concerns that these changes found in a sequence designated by the CDC as a low reactor, have spread throughout the northern hemisphere. In addition to A/Victoria/361-like sequences with T128A, the second low reactor, A/Hawaii/29/2012, with L157S is also raising concerns. Today the CDC released sequences for A/Hawaii/22/2012 X-225A which is being tested as a new H3N2 vaccine target which has L157S. Media Link Recombinomics Presentations Recombinomics Publications Recombinomics Paper at Nature Precedings

Home | Founder | What's New | In The News | Contact Us